Insurer Humana’s quarterly profit climbs 13 percent
Humana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint Inc.
Health Care Businesses
Articles
Ortho firms pull back on doc payments
The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.
Lilly wins European approval for new use of Alimta
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
Hill-Rom sees better earnings, revenue in quarter
Hill-Rom Holdings Inc. posted better-than-expected earnings and revenue in its fiscal fourth quarter, the Batesville-based hospital-bed supplier announced Wednesday.
Lilly diabetes drug wins approval for expanded use
Eli Lilly and Co. and Amylin Pharmaceuticals Inc.’s Byetta has received expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.
Lilly announces replacements for two retiring executives
Bryce Carmine, president of Lilly’s bio-medicines division, and Frank Deane, president of Lilly’s global manufacturing operations, both will retire on Dec. 31.
Lilly CEO says he’s not interested in Pfizer animal unit
Drugmaker Eli Lilly and Co. doesn’t plan to buy Pfizer Inc.’s $3.58 billion animal-health business, CEO John Lechleiter said Wednesday.
Eli Lilly, Turkish firm in talks to sell drugs in 26 nations
Eli Lilly and Co., the world’s biggest maker of psychiatric drugs, is in talks with Mustafa Nevzat Ilac Sanayii AS to sell the Turkish company’s treatments in 26 countries, said Mustafa Nevzat’s CEO.
Q&A
Dr. Ed Kowlowitz, owner and medical director of the Center for Pain Management in Indianapolis, recently challenged a regional Medicare reimbursement policy and, surprisingly, won. He spoke with IBJ about the experience, as well how his three-physician practice is growing even while many physician practices are selling to hospitals.
Lilly’s Alimta get favorable opinion for new use in Europe
If approved for continuation maintenance, Eli Lilly and Co.’s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
Carmel-based company buys medical-billing firm
Zotec Partners, a fast-growing physician-billing management company based in Carmel, has acquired a family-owned medical-billing firm with 100 employees based in Florida.
FDA gets new report on Lilly diabetes drug
Drugmakers Eli Lilly and Co. and Amylin Pharmaceuticals Inc. said Monday that patients taking their potential once-weekly diabetes treatment, Bydureon, saw a significant improvement in cardiovascular risk factors.
FDA deal with drugmakers raises user fees 6 percent
Drugmakers including Eli Lilly an Co. have agreed with regulators on a 6-percent increase in review fees as part of reauthorizing the drug-approval process through fiscal 2017.
Private firm with Medicaid deal gets state help
Officials with the Missouri Department of Health and Senior Services say they had to hire 13 temporary workers and shift as many as 20 state workers from their regular jobs after withering consumer complaints against SynCare LLC of Indiana.
Missouri health care advocates decry Indiana contractor
Indianapolis-based SynCare LLC, hired to determine the eligibility of Missouri Medicaid patients for in-home care, has "been a complete disaster from the beginning," statewide health care advocates charge.
Arcadia Resources to delist stock amid cash crunch
Arcadia Resources Inc.’s share price dwindled to just 5 cents as of late Tuesday morning, following the company's announcement that it was delisting its stock and had suffered another quarterly loss.
Orthopedics company plans $27M Indiana project
Warsaw-based DePuy Orthopaedics expects to spend $20 million on manufacturing equipment and $7 million on research and development equipment and have it installed before 2014.
Endocyte completes secondary public offering
The West Lafayette-based biotech firm raised about $66.8 million by selling nearly 6.7 million shares of company stock, priced at $12.26 per share.
Lilly wins appeals court ruling in Strattera patent case
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., overturned Friday a judge’s decision that Lilly’s patent on attention-deficit treatment Strattera was invalid.
Lilly stock rises after drugmaker reports higher sales
Investors responded favorably Thursday to Eli Lilly and Co.’s surprisingly strong second-quarter revenue, even though its profit fell due to rapid spending on marketing and research.